ZP General Partner 3 ApS: Financial statements 2023
CVR: 41023422
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
ZP General Partner 3 ApS (CVR 41023422) has filed annual accounts for 2023. In 2023, the company reported revenue of DKK 1,000 and a net result of DKK -14,000 compared with DKK -24,000 the year before. The profit margin was -1,400%. Equity in the 2023 report amounted to DKK 8,000. The solvency ratio was 40%.
- Revenue
- DKK 1,000
- Gross Profit
- DKK 1,000
- Profit/Loss
- DKK -14,000
- Equity
- DKK 8,000
- Total Assets
- DKK 20,000
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 1K | 1K | -14K | 8K | - |
| 2022 | 1K | 1K | -24K | 22K | - |
| 2021 | 0 USD | 0 USD | -1K USD | 7K USD | - |
| 2020 | 280K USD | -279K USD | 218K USD | 245K USD | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
ZP General Partner 3 ApS has published its annual report for 2022. Revenue came to DKK 1,000, and the net result was DKK -24,000.
About ZP General Partner 3 ApS
ZP General Partner 3 ApS is a Danish company of the type Anpartsselskab based in Søborg, founded in 2019. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Adam Sinding Steensberg and Henriette Wennicke. The company is owned by ZEALAND PHARMA A/S. In 2025, the company reported revenue of DKK 1,000 and a net result of DKK -29,000 compared with DKK -18,000 the year before. Equity in the 2025 report amounted to DKK 30,000.